Future research directions in idiopathic pulmonary fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group

Ronald Crystal, Peter B. Bitterman, Brooke Mossman, Marvin I. Schwarz, Dean Sheppard, Laura Almasy, Harold A. Chapman, Scott L. Friedman, Talmadge E. King, Leslie A. Leinwand, Lance Liotta, George R. Martin, David A. Schwartz, Gregory S. Schultz, Carston R. Wagner, Robert A. Musson

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.

Original languageEnglish
Pages (from-to)236-246
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume166
Issue number2
DOIs
Publication statusPublished - 15 Jul 2002
Externally publishedYes

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Idiopathic Pulmonary Fibrosis
Molecular Diagnostic Techniques
Laser Capture Microdissection
Human Genome Project
Pulmonary Fibrosis
Therapeutics
Research
Animal Models
Direction compound
Inflammation
Technology
Proteins

Keywords

  • Lung diseases, interstitial
  • National Institutes of Health (United States)
  • Pulmonary fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Future research directions in idiopathic pulmonary fibrosis : Summary of a National Heart, Lung, and Blood Institute Working Group. / Crystal, Ronald; Bitterman, Peter B.; Mossman, Brooke; Schwarz, Marvin I.; Sheppard, Dean; Almasy, Laura; Chapman, Harold A.; Friedman, Scott L.; King, Talmadge E.; Leinwand, Leslie A.; Liotta, Lance; Martin, George R.; Schwartz, David A.; Schultz, Gregory S.; Wagner, Carston R.; Musson, Robert A.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 166, No. 2, 15.07.2002, p. 236-246.

Research output: Contribution to journalArticle

Crystal, R, Bitterman, PB, Mossman, B, Schwarz, MI, Sheppard, D, Almasy, L, Chapman, HA, Friedman, SL, King, TE, Leinwand, LA, Liotta, L, Martin, GR, Schwartz, DA, Schultz, GS, Wagner, CR & Musson, RA 2002, 'Future research directions in idiopathic pulmonary fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group', American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 236-246. https://doi.org/10.1164/rccm.2201069
Crystal, Ronald ; Bitterman, Peter B. ; Mossman, Brooke ; Schwarz, Marvin I. ; Sheppard, Dean ; Almasy, Laura ; Chapman, Harold A. ; Friedman, Scott L. ; King, Talmadge E. ; Leinwand, Leslie A. ; Liotta, Lance ; Martin, George R. ; Schwartz, David A. ; Schultz, Gregory S. ; Wagner, Carston R. ; Musson, Robert A. / Future research directions in idiopathic pulmonary fibrosis : Summary of a National Heart, Lung, and Blood Institute Working Group. In: American Journal of Respiratory and Critical Care Medicine. 2002 ; Vol. 166, No. 2. pp. 236-246.
@article{68520404b80843288966daf8e56b8b6f,
title = "Future research directions in idiopathic pulmonary fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group",
abstract = "Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.",
keywords = "Lung diseases, interstitial, National Institutes of Health (United States), Pulmonary fibrosis",
author = "Ronald Crystal and Bitterman, {Peter B.} and Brooke Mossman and Schwarz, {Marvin I.} and Dean Sheppard and Laura Almasy and Chapman, {Harold A.} and Friedman, {Scott L.} and King, {Talmadge E.} and Leinwand, {Leslie A.} and Lance Liotta and Martin, {George R.} and Schwartz, {David A.} and Schultz, {Gregory S.} and Wagner, {Carston R.} and Musson, {Robert A.}",
year = "2002",
month = "7",
day = "15",
doi = "10.1164/rccm.2201069",
language = "English",
volume = "166",
pages = "236--246",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Future research directions in idiopathic pulmonary fibrosis

T2 - Summary of a National Heart, Lung, and Blood Institute Working Group

AU - Crystal, Ronald

AU - Bitterman, Peter B.

AU - Mossman, Brooke

AU - Schwarz, Marvin I.

AU - Sheppard, Dean

AU - Almasy, Laura

AU - Chapman, Harold A.

AU - Friedman, Scott L.

AU - King, Talmadge E.

AU - Leinwand, Leslie A.

AU - Liotta, Lance

AU - Martin, George R.

AU - Schwartz, David A.

AU - Schultz, Gregory S.

AU - Wagner, Carston R.

AU - Musson, Robert A.

PY - 2002/7/15

Y1 - 2002/7/15

N2 - Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.

AB - Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before diagnosis are unknown, and for which existing treatments are of limited benefit. The National Heart, Lung, and Blood Institute convened a working group to develop specific recommendations for future IPF research. Inflammatory and immune processes are involved in IPF pathogenesis, and current therapeutic strategies are aimed at suppressing the inflammation. Recent data suggest that the molecular processes underlying the fibrogenesis may provide new opportunities for therapeutic intervention. Specific areas of future research recommended by the working group include studies to elucidate the etiology of IPF, to develop novel diagnostic techniques and molecular diagnostics, to establish a program for identification of molecular targets for IPF treatment and identification and generation of agonists or antagonists that inhibit fibrogenesis, to foster investigations that couple the use of new technologies (e.g., laser capture microdissection, microarrays, and mass spectroscopic analysis of proteins) with data from the human genome project, to establish a national consortium of Clinical Centers of Excellence to conduct coordinated clinical and laboratory studies of well-characterized patients and patient-derived materials, and to stimulate research to develop animal models of persistent and progressive pulmonary fibrosis for evaluation of new intervention approaches.

KW - Lung diseases, interstitial

KW - National Institutes of Health (United States)

KW - Pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=0037099443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037099443&partnerID=8YFLogxK

U2 - 10.1164/rccm.2201069

DO - 10.1164/rccm.2201069

M3 - Article

C2 - 12119236

AN - SCOPUS:0037099443

VL - 166

SP - 236

EP - 246

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -